Blood-Brain Barrier Transporters

Mastering a CNS pharmacotherapy strategy to explore transporters to enhance drug delivery in the brain

In the Chair:

Dr. Janet Hoogstraate Director DMPK

ASTRAZENECA

Hear from your eminent Speaker Panel:

Dr. Anders Haegerstrand Vice President and Chief Scientific Officer

NEURONOVA

Dr. Lars U. Wahlberg Executive Vice President and Chief Operating Officer

NSGENE

Dr Mohammad S. Alavijeh Managing Director

PHARMIDEX

Berend Oosterhuis, Director of Business Development and Contract Research Services

SOLVO BIOTECHNOLOGY

Dr. Björn Bauer Assistant Professor

UNIVERSITY OF MINNESOTA (USA)

Associate Professor Eric V. Shusta Department of Chemical & Biological Engineering

UNIVERSITY OF WISCONSIN-MADISON (USA)

Professor Jens Pahnke Head of the NRL and Head of the DZNE Biomarker and Autopsy Study

UNIVERSITY OF ROSTOCK

Event Summary:

The World is facing tremendous challenges in the coming years with a rapidly aging population who might suffer from neurodegenerative conditions. This will be a burden for health services in many countries both economically and socially. To overcome these challenges, the Life Science industry and the academic community work in partnership to accelerate scientific discoveries to prevent or slow down the progression of Alzheimer’s disease and Parkinsons disease.

The super family ABC transporter proteins have come into CNS pharmacotherapy recently to facilitate the clearance of neurotoxic proteins. Age-related neurodegenerative disorders have in common the accumulation of insoluble neurotoxic proteins. Proteins that become toxic within the brain are detoxified or cleared from the brain. MDR1 and P-glycoprotein transporters represent a brand new master drug target for multidrug resistance from proteins. P-glycoprotein transporters possess capabilities to pump out beta-amyloid plaques through the blood-brain barrier to prevent an inflammatory response in the brain that could damage nerve cells. MDR1 and P-glycoprotein transporters are a new drug target strategy to enhance drug delivery to the brain in order to prevent or slow down the progression of dementia such as Alzheimer’s and Parkinsons disease.

This executive CNS event will examine the role of transporters to support a CNS pharmacotherapy strategy to deliver innovative treatment regimes to successfully combat Alzheimer’s and Parkinsons disease. Our distinguished speaker panel will provide your company with a road map to successfully draw up strategies to cross the BBB and enhance drug discovery in the human brain. This conference will enable your company to position itself as a frontrunner being able to launch safe and innovative CNS drug treatments for a growing population of elderly people the next decades.

This event will tackle key issues such as:

• Launching a common strategic research agenda on neurodegenerative conditions to find a cure and enable early diagnosis
• Designing a pharmacotherapy approach to enhance MDR1 & P-glycoprotein transporters for poly-specific drug binding
• Examining the regulation of blood-brain barrier drug efflux transporters to improve CNS disease pharmacotherapy
• Improving antibody-based brain drug delivery to prevent further progression of dementia conditions
• How do you best pool resources and research investments to improve existing Alzheimer’s disease treatments drug delivery capabilities in the brain?
• Alzheimer’s disease & the blood-brain barrier function: Activating BBC transport molecules to reduce soluble toxic AB oligomers
• Developing partnerships in the Life Science industry to launch second-generation active Abeta immunotherapy to fight Alzheimer’s disease
• Identifying the right set of PD/AD biomarkers and brain imaging technologies to monitor P-glycoprotein transporters across the blood-brain barrier
• Increasing the knowledge about ABC Transporters and P-glycoprotein to maximise the potential of your anti-AB immunotherapy approach
• Exploring re-engineering processes to target anti-Abeta monoclonal drugs to treat Alzheimer’s disease
• Neurotherapeutic bi-functionality: Creating a novel fusion antibody to cross the human BBB and act at specific drug receptors inside the brain
• Designing clinical trials to successfully deliver your Alzheimer’s disease treatments to the market

Target audience and Job titles:

Presidents, Chief Executive Officers, Chief Scientific Officers, Chief Medical Officers, Vice Presidents, Directors and Heads within:

• Neuroscience

• Drug Metabolism and Pharmacokinetics (DMPK)

• Research & Development

• Neurodegeneration

• Pharmacogenomics

• Parkinson’s Disease Research

• Immunology & Antibody Engineering

• Pharma Research, Development and Medicine

• Alzheimer’s Disease R & D

• Central Nervous System (CNS) Research

• Molecular and Developmental Genetics

• Discovery Research and Preclinical Development

• Antibody Discovery

• Clinical Development Neuroscience

• Molecular Neurobiology

• Drug Development

• Neuroscience Research

• Discovery & Engineering

• Drug Discovery PD/AD

• Neurology and Neurological Sciences

• Neurobiology

• Discovery

• Alzheimer's Disease Research

• Clinical Neuroscience

• Business Development - Neuroscience